Physiological Responses to U-LABA/ICS With Emphasis on Exercise Performance in Well-Trained Individuals, Formoterol
Overview
- Phase
- Not Applicable
- Intervention
- Symbicort
- Conditions
- Exercise Performance
- Sponsor
- Morten Hostrup, PhD
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Power output during time trial
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The purpose of the project is to investigate exercise performance in well-trained individuals in a crossover design following varying degrees of bronchodilation/constriction intervention using current standard procedures.
Investigators
Morten Hostrup, PhD
Associate Professor
University of Copenhagen
Eligibility Criteria
Inclusion Criteria
- •Age 18-45
- •Physically active \>5 hours a week
- •Maximum oxygen uptake classified as high or very high
Exclusion Criteria
- •Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
- •ECG abnormality
- •FEV1/FVC ratio \< 0,7 determined with spirometry
- •Chronic illness determined to be a potential risk for participant during the study
- •In chronic treatments with medication that may interfere with study results
- •Pregnancy
- •Blood donation during the past 3 months
Arms & Interventions
Symbicort - usual care
Participants are administered Formoterol + Budesonide from an inhaler device testing. In addition, participants are administered a placebo capsule, which is taken orally.
Intervention: Symbicort
Formoterol - inhalation
Participants are administered Formoterol from an inhaler device testing. In addition, participants are administered a placebo capsule, which is taken orally.
Intervention: Formoterol
Formoterol - oral
Participants are administered a Formoterol capsule, which is taken orally. In addition, participants are administered placebo from an inhaler device.
Intervention: Formoterol
Placebo
Participants are administered placebo from an inhaler device testing and a placebo capsule.
Intervention: Placebo
Mannitol-test
Participants are administered Bronchitol from an inhaler device testing.
Intervention: Mannitol
Outcomes
Primary Outcomes
Power output during time trial
Time Frame: Through study completion, an average on 4 weeks
Mean power output measured in Watts during a time trial on a bike ergometer
Secondary Outcomes
- Power output during sprint testing(Through study completion, an average on 4 weeks)